JASTLabs — Clinical Angle | Invest in a Women's Health Company Targeting a $24B Untreated Market
Early-Stage Clinical Investment Opportunity

Invest In A Women's Health Company Targeting A $24B Untreated Market Built on Proven Clinical Science

A non-estrogen, topical solution leveraging known physiological pathways, already being applied in real-world clinical settings and structured for scalable commercialization.

See the full offering, review the terms, and join the raise while it is open.

Invest Now
505(b)(2) Regulatory Pathway
Built on 2 Approved Compounds
Active Real-World Clinical Use
Ex-Pfizer Commercial Leadership
The Model

De-Risking the Science. Built to Scale

Why investors are paying attention to this model now

Massive, Underserved Market

Up to 47% of women experience menopause-related symptoms, yet treatment adoption remains low.

Clear Demand for Non-Estrogen Solutions

Existing treatments are not suitable for many women because of contraindications or elevated risk factors, creating strong demand for safer alternatives.

Built on Proven Compounds

Uses widely studied compounds with known safety and biological effects.

No Discovery Risk

By utilizing previously approved molecules, we bypass the years of high-failure-rate lab research typical of traditional biotech.

Active Clinical Application

Currently being utilized by patients in real-world clinical environments, validating efficacy early.

Structured for Efficient Scale

Leveraging a faster regulatory pathway with a model designed for efficient commercial scale.

Review the investment opportunity
The Gap

A Structural Gap in Standard of Care

Despite clear clinical awareness, this category remains underserved due to limitations in current treatment frameworks.

Hormone-Based Limitation

The standard of care relies heavily on estrogen-based therapies, which are not suitable for a large segment of patients.

Innovation Bottleneck

Traditional drug development requires long timelines, high capital, and carries significant failure risk, slowing progress in this category.

Mismatch Between Need and Adoption

While symptoms are widely recognized in clinical practice, treatment adoption remains low due to safety concerns and limited options.

Timing Shift

Advances in formulation, combined with changing patient preferences, are creating a window for new, non-hormonal approaches to emerge.

The Approach

A New Approach to Women's Intimacy & Menopause Care

A non-estrogen, topical formulation built on validated compounds, structured for real-world clinical application and scalable commercialization.

JL-112 is a topical, non-estrogen formulation designed to address menopause-related symptoms by combining two widely studied compounds with established biological effects.

Rather than relying on new molecule discovery, this approach applies known physiological pathways in a simplified, targeted format.

Because these compounds are already well understood, the model reduces development complexity while creating a more efficient path to clinical adoption and scale.

Known mechanisms. Applied differently. Built to scale.

Validation

Already in Use. Already Validated.

Currently being applied in real-world clinical settings.

Active Clinical Use: Currently being applied with patients in clinical environments.

Established Safety Profile: Built on compounds with known safety and widespread use.

Observed Demand Signal: Early indication of demand within an underserved category.

Clear Path to Scale: Transitioning from clinical application to structured commercialization.

The Team

The Playbook to Navigate Pharma

Executed by Those Who Wrote It

Medical plausibility requires structured commercial execution to realize investor returns.

Big Pharma Pedigree

Former Pfizer executive bringing over three decades of direct pharmaceutical growth and commercialization experience.

Regulatory Pattern Recognition

Deep, proven expertise in navigating complex FDA pathways, driving medical research to market-accepted outcomes.

Built for Commercial Scale

Leadership is structurally aligned to formalize this clinical model into a scalable commercial brand, positioning the asset for broad pharmaceutical distribution when ready.

Michael Rubin, CEO
Michael RubinCEO
Review the investment opportunity
The Timing

The Timing is Now: Surging Demand Meets De-Risked Science

Rising demand, validated science, and a clear gap are converging at the same time.

Growing Market Attention

Global focus and capital are rapidly shifting toward women's health innovation.

Clear White Space

The gap between patient suffering and available treatments remains a measurable, multi-billion dollar void.

Validated Mechanics

Built on a physiological framework the medical and pharmaceutical communities already trust.

Strategic Entry

Access this opportunity during its crucial formalization phase, prior to major institutional funding.

Right market. Proven foundation. Timed for scale.
The Path

Clear Path to Market

Built to scale with the intention to commercialize through well-established pharma product distribution, when ready.

Built to become a scalable women's health asset with long-term commercial value.

Review the investment opportunity

The company is being developed with a clear objective:

to translate early clinical use into a structured, scalable product positioned for well-established pharmaceutical distribution, when ready.

This category is ready: demand is growing, current care leaves room for improvement, and the team is focused, resourced, and experienced in both clinical application and commercialization through established pharmaceutical channels.

By combining validated science with a simplified, capital-efficient path, the company is positioned to move from early-stage development into a women's health asset with a clear path toward broader commercial distribution.

From clinical use → commercial adoption → broader pharmaceutical distribution.

FAQ

FAQ

Due Diligence Starts Here
A non-estrogen, topical formulation combining two widely studied compounds (Sildenafil and Oxytocin) into a single application.
It uses previously approved compounds and follows the 505(b)(2) pathway—reducing time, cost, and early-stage failure risk.
Yes. The formulation is currently being applied in real-world clinical settings.
Current treatments are largely hormone-based, limiting adoption due to safety concerns and contraindications.
It expands access to patients who cannot or choose not to use hormone-based therapies.
It combines known pathways associated with blood flow and tissue response, using compounds already understood in medical practice.
Yes. Patent applications have been filed, with ongoing efforts to strengthen global protection.
Led by a former Pfizer executive with 30+ years of experience in pharma commercialization and regulatory pathways.
Preparing for FDA engagement under the 505(b)(2) pathway following formulation and stability work.
The strategy is to scale JL-112 into a product opportunity positioned for broader pharmaceutical distribution and commercial growth, when ready.

Evaluate the Science. Review the Economics.

See exactly how we are leveraging established clinical logic to capture a multi-billion dollar healthcare gap.
Request the offering & view the pitch deck

For accredited investors seeking a clinically grounded healthcare thesis.

The securities offered hereby have not been registered under the Securities Act of 1933, as amended (the "Act"), or any state securities or blue sky laws and are being offered and sold in reliance on exemptions from the registration requirements of the Act and state securities or blue sky laws. Accordingly, the securities cannot be sold or otherwise transferred except in compliance with the Act. In addition, the securities cannot be sold or otherwise transferred except in compliance with the applicable state securities or blue sky laws. The securities have not been approved or disapproved by the SEC, any state securities commission or other regulatory authority, nor have any of the foregoing authorities passed upon the merits of this offering or the adequacy or accuracy of any other materials or information made available to subscriber in connection with this offering. Any representation to the contrary is unlawful.

The securities may only be purchased by persons who are "accredited investors" (as that term is defined in Section 501 of Regulation D promulgated under the Act).

The offering materials may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company's management. When used in the offering materials, the words "estimate," "project," "believe," "anticipate," "intend," "expect" and similar expressions are intended to identify forward-looking statements, which constitute forward-looking statements. These statements reflect management's current views with respect to future events and are subject to risks and uncertainties that could cause the company's actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events